These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 10709570)

  • 1. New agents in glaucoma therapy.
    Kooner KS
    Int Ophthalmol Clin; 1999; 39(3):1-15. PubMed ID: 10709570
    [No Abstract]   [Full Text] [Related]  

  • 2. New aqueous inflow inhibitors.
    Doyle JW; Smith MF
    Semin Ophthalmol; 1999 Sep; 14(3):159-63. PubMed ID: 10790580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbonic anhydrase inhibitors as fourth drug in primary glaucomas: Is it worth it?
    Juncal VR; Abdo Jorge F; Paranhos A; Santos Prata T
    Can J Ophthalmol; 2015 Aug; 50(4):297-301. PubMed ID: 26257224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of fixed-dose combination drugs for the treatment of glaucoma.
    Khouri AS; Realini T; Fechtner RD
    Drugs Aging; 2007; 24(12):1007-16. PubMed ID: 18020533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pleiotropic effects in local drug treatment for glaucoma].
    Erb C
    Klin Monbl Augenheilkd; 2013 Feb; 230(2):141-5. PubMed ID: 23430678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Azarga, a new and useful fixed combination in glaucoma treatment].
    Călugăru M; Călugăru D
    Oftalmologia; 2011; 55(3):38-46. PubMed ID: 22428291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fixed combinations of dorzolamide-timolol and brimonidine-timolol in the management of glaucoma.
    Razeghinejad MR; Sawchyn AK; Katz LJ
    Expert Opin Pharmacother; 2010 Apr; 11(6):959-68. PubMed ID: 20307220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mode of action, clinical profile and relevance of carbonic anhydrase inhibitors in glaucoma therapy].
    Eichhorn M
    Klin Monbl Augenheilkd; 2013 Feb; 230(2):146-9. PubMed ID: 23430679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New developments in drug therapy of glaucoma].
    Pfeiffer N
    Ophthalmologe; 1992 Feb; 89(1):W1-13. PubMed ID: 1349844
    [No Abstract]   [Full Text] [Related]  

  • 10. Costs and persistence of carbonic anhydrase inhibitor versus alpha-2 agonists, associated with beta-blockers, in glaucoma and ocular hypertension: an analysis of the UK-GPRD database.
    Lafuma A; Berdeaux G
    Curr Med Res Opin; 2008 May; 24(5):1519-27. PubMed ID: 18413015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension.
    Stewart WC; Sharpe ED; Day DG; Kolker AE; Konstas AG; Lee WH; Rieser JC; Chopra H; Holmes KT
    J Ocul Pharmacol Ther; 2000 Jun; 16(3):251-9. PubMed ID: 10872922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical treatment of glaucoma and the promising perspectives.
    Diestelhorst M
    Curr Opin Ophthalmol; 1996 Apr; 7(2):18-23. PubMed ID: 10163316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additive intraocular pressure lowering effect of various medications with latanoprost.
    O'Connor DJ; Martone JF; Mead A
    Am J Ophthalmol; 2002 Jun; 133(6):836-7. PubMed ID: 12036683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short- and long-term safety of glaucoma drugs.
    Schuman JS
    Expert Opin Drug Saf; 2002 Jul; 1(2):181-94. PubMed ID: 12904152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis of the efficacy and safety of alpha2-adrenergic agonists, beta-adrenergic antagonists, and topical carbonic anhydrase inhibitors with prostaglandin analogs.
    Tanna AP; Rademaker AW; Stewart WC; Feldman RM
    Arch Ophthalmol; 2010 Jul; 128(7):825-33. PubMed ID: 20625041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative acute effects of brimonidine 0.2% versus dorzolamide 2% combined with beta-blockers in glaucoma.
    Centofanti M; Manni G; Gregori D; Cocco F; Lorenzano D; Bucci MG
    Graefes Arch Clin Exp Ophthalmol; 2000 Apr; 238(4):302-5. PubMed ID: 10853928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological advances in the treatment of glaucoma.
    Serle JB
    Drugs Aging; 1994 Sep; 5(3):156-70. PubMed ID: 7803944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New medical treatments for glaucoma.
    Novack GD; Robin AL; Derick RJ
    Int Ophthalmol Clin; 1993; 33(4):183-202. PubMed ID: 7903082
    [No Abstract]   [Full Text] [Related]  

  • 19. The use of latanoprost 0.005% once daily and its effect on intraocular pressure as primary or adjunctive therapy.
    Smith SL; Sine CS; Pruitt CA; Stewart WC
    J Ocul Pharmacol Ther; 1999 Feb; 15(1):29-39. PubMed ID: 10048345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of new drugs on management of glaucoma in Scotland: observational study.
    Bateman DN; Clark R; Azuara-Blanco A; Bain M; Forrest J
    BMJ; 2001 Dec; 323(7326):1401-2. PubMed ID: 11744564
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.